CoronaVac (Sinovac)
phone-call sandwich
CoronaVac (Sinovac)

CoronaVac (Sinovac)

CoronaVac is a vaccine against COVID-19 developed by China biopharmaceutical company Sinovac. The vaccine is a chemically inactive whole-virion vaccine against COVID-19. The WHO approved the vaccine for emergency use on June 1, 2021.
CoronaVac

CoronaVac

On December 13, the Butantan Institute in Brazil announced that 170 cases of COVID-19 had been registered in Phase III trials, over the 151-case threshold required for initial analysis. It followed by stating that documentation would be submitted to both the Brazilian National Health Regulatory Agency (ANVISA) and China’s National Medical Products Administration on December 23 for full approval. Some studies claim that the virus provides lower overall protection than the seven other WHO-approved vaccines; still, tests now show that Sinovac’s CoronaVac is 100% effective in preventing serious illness and death.

Vaccine

CoronaVac

Developer

Sinovac Biotech., China

Producer

The vaccine was developed by the Chinese biopharmaceutical company Sinovac Biotech. CoronaVac is the second Chinese-made vaccine approved for use in China (after the vaccine made by Sinopharm).

Стадия

Phase III trials of Sinovac's vaccine are underway in Brazil, Indonesia and Turkey. In China and Indonesia, the vaccine is approved for emergency vaccination. Despite the fact that the vaccine’s effectiveness is still under examination, Sinovac is planning mass production for export.

Key information

What’s in the vaccine?

The vaccine is a chemically inactive whole-virion vaccine against COVID-19.



Vaccines developed and used in Russia